

10/576761

14APR2006 RCD PCT/PTO 51 APR 2006

"Express Mail" mailing label number

832895625 US

Date of Deposit

APR. 21, 2006

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

QUEEN Thomas  
Printed Name

Breanna Thomas  
Signature

**PATENT APPLICATION  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: Konstantinos Gavardinas  
For: TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR  
MODULATORS

Docket No.: X-16534

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of documents BA-BG and reference CA for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b),  
Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

Alexander Wilson

Alexander Wilson  
Attorney for Applicant(s)  
Registration No. 45,782  
Phone: 317-277-0190

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288  
14 April 2006.

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-16534	Serial No. <b>10/576761</b>
	First Applicant Konstantinos Gavardinas	
	Filing Date	Group

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. 1	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US 4,999,363	March 12, 1991	Oshima, et al.	
	AB	US 5,024,912	June 18, 1991	Neishi, et al.	
	AC	US 5,093,210	March 3, 1992	Ohta, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	WO 2004/052847	June 24, 2004	Eli Lilly and Company		
	BB	WO 03/078394	September 25, 2003	Eli Lilly and Company		
	BC	WO 03/053358	July 3, 2003	Bristol-Myers Squibb Co.		
	BD	JP04046352	February 17, 1992	Minolta Camera Co.		Yes
	BE	JP01161245	June 23, 1989	Canon, Inc.		Yes
	BF	WO99/33786	July 8, 1999	Ortho-McNeil Pharmaceutical		
	BG	WO 00/059884	October 12, 2000	Dana-Farber Cancer Institute		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CA	Cheng, et al, "Synthesis and Structure-Activity Relationships of 9-Substituted Acridines as Endothelin-A Receptor Antagonists," <i>Bioorganic and Medicinal Chemistry Letters</i> , Vol. 6, No. 24, pgs. 2999-3002 (1996)	
	CB		

Examiner Signature	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.